The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Search for "certolizumab pegol"

Search results for: certolizumab pegol

Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis

June 27, 2019 • By Arthritis & Rheumatology

Adding certolizumab pegol to background medication is better than adding a placebo for patients with active nonradiographic axial spondyloarthritis, according to a new study…... [Read More]

Filed Under: Conditions, Spondyloarthritis Tagged With: Arthritis & Rheumatology, axial spondyloarthritis (SpA), Certolizumab Pegol

Health Canada Approves Certolizumab Pegol & NICE Issues Guidance for Certolizumab Pegol

May 7, 2019 • By Michele B. Kaufman, PharmD, BCGP

Certolizumab pegol has been approved in Canada for treating adults with plaque psoriasis. The U.K. has also issued its final guidance for the treatment’s use…... [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: breastfeeding, Canada, Certolizumab Pegol, NICE, plaque psoriasis, pregnant women, U.K.

FDA Approves Certolizumab Pegol for Treating Non-Radiographic Axial SpA

April 30, 2019 • By Michele B. Kaufman, PharmD, BCGP

Certolizumab pegol is now FDA approved to treat adults with active non-radiographic axial spondyloarthritis…... [Read More]

Filed Under: Drug Updates Tagged With: axial spondyloarthritis (SpA), Certolizumab Pegol, FDA, non-radiographic axial spondyloarthritis, U.S. Food and Drug Administration (FDA)

Certolizumab Pegol Receives FDA Approval for Plaque Psoriasis

June 18, 2018 • By Michele B. Kaufman, PharmD, BCGP

On the basis of data from multiple clinical trials, the FDA has approved certolizumab pegol for treating moderate to severe plaque psoriasis…... [Read More]

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: Certolizumab Pegol, FDA, FDA approval, plaque psoriasis, Psoriasis, U.S. Food and Drug Administration (FDA)

Ixekizumab Promising for AS; Plus Certolizumab Pegol Studied for Psoriasis

March 14, 2018 • By Michele B. Kaufman, PharmD, BCGP

In a Phase 3 study, ixekizumab proved safe and effective to treat adults with ankylosing spondylitis (AS)…... [Read More]

Filed Under: DMARDs & Immunosuppressives, Drug Updates, Spondyloarthritis Tagged With: Ankylosing Spondylitis, Certolizumab Pegol, ixekizumab, Psoriasis

EU Approves Certolizumab Pegol for Pregnant & Nursing Patients

January 23, 2018 • By Michele B. Kaufman, PharmD, BCGP

In the EU, certolizumab pegol has been approved for use in pregnant and nursing women with chronic rheumatic disease…... [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates, Research Reviews Tagged With: breast milk, breastfeeding, Certolizumab Pegol, European Medicines Agency, pregnancy, pregnant women

Certolizumab Pegol Promising for Plaque Psoriasis in Phase 3 Trial

March 1, 2017 • By Michele B. Kaufman, PharmD, BCGP

Certolizumab pegol has proved safe and effective for treating patients with plaque psoriasis in a Phase 3 clinical trial…... [Read More]

Filed Under: Biologics & Biosimilars, Conditions, Drug Updates, Scleroderma Tagged With: Certolizumab Pegol, etanercept, plaque psoriasis

Certolizumab Pegol Usage Compatible with Breastfeeding

December 20, 2016 • By Michele B. Kaufman, PharmD, BCGP

In a small-scale study, researchers found that no, or minimal amounts of, certolizumab pegol transfers from mothers taking the drug to nursing infants…... [Read More]

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: breast milk, breastfeeding, Certolizumab Pegol, infants, pregnancy

Certolizumab Pegol Combination Therapy Better than Methotrexate Monotherapy in DMARD-Naive Patients with RA

June 29, 2016 • By Michele B. Kaufman, PharmD, BCGP

A recent study found that certolizumab pegol plus methotrexate is effective in achieving sustained remission and low disease activity in patients with early active RA…... [Read More]

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: Certolizumab Pegol, combination therapy, disease-modifying antirheumatic drugs, Methotrexate

Certolizumab Pegol Effective for Treating Rheumatoid Arthritis

July 19, 2015 • By Reuters Staff

NEW YORK (Reuters Health)—Certolizumab pegol, a humanized anti-TNF antibody fragment conjugated to polyethylene glycol, is effective for treating early rheumatoid arthritis (RA) with poor prognostic factors, according to results from the C-OPERA study. Certolizumab is approved in the U.S. and other countries for treating inflammatory diseases, including RA, but its effectiveness in methotrexate-naïve early RA… [Read More]

Filed Under: Biologics & Biosimilars, Conditions, Drug Updates, Rheumatoid Arthritis Tagged With: anti-TNF agent, Certolizumab Pegol, Methotrexate, Rheumatiod arthritis

  • 1
  • 2
  • 3
  • …
  • 6
  • Next Page »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

This site uses cookies: Find out more.